HemaFus ETV6-RUNX1 Fusion Gene Qualitative Detection Kit (PCR-Fluorescent Probing)

Background

The ETV6-RUNX1 (TEL-AML1) fusion gene, formed by the t(12;21)(p13;q22) translocation (Figure 1), is the most frequent abnormality in childhood ALL (approx. 25% of childhood B-ALL), and t (12;21) has not been found in T-ALL, AML, or NHL so far, even rarely reported in infant leukemia, and much rarer in adult leukemia (< 2%). The ETV6-RUNX1 fusion gene is an independent prognostic factor, and such patients respond well to treatment, with a long duration of complete remission and good prognosis.

Figure 1

Features

Simple operation and less time consumption; reliable results and intuitive interpretation; high sensitivity and sample saving.

Detection Process

In this method, RNA is isolated and purified from leukocytes in peripheral blood or bone marrow samples, and cDNA is obtained by reverse transcription to qualitatively detect the ETV6-RUNX1 fusion gene by fluorescence quantitative PCR.
The fusion of fusion genes is shown in Figure 2.

Figure 2

Applicable instrument

ABI fluorescence quantitative PCR system (ABI7500, ABI ViiA7)

Ordering Information